MAIA Biotechnology grants director 32,012 options

The options vested in full on the grant date and may be exercised at $1.18 per share through September 30, 2036.

Rhea-AI Filing Summary

MAIA Biotechnology, Inc. director Theagene Jean-Manasse received a grant of 32,012 stock options on September 30, 2026, under the company’s 2021 Equity Incentive Plan. The options vested 100% on the grant date and became exercisable that day at $1.18 per share. They expire September 30, 2036. His reported post-transaction position is 32,012 stock options.

Insider Trade Summary

Grant/Award: 32,012 shares

Grant/Award 1 txn

Insider Theagene Jean-Manasse

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options F1	32,012	$0.00	$0.00

Holdings After Transaction: Stock Options — 32,012 contracts (Direct)

Footnotes (1)

1. F1. The stock options, granted on September 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

Key Figures

Stock options granted: 32,012 options Exercise price: $1.18 per share Vesting: 100% +2 more

5 metrics

Stock options granted 32,012 options Granted September 30, 2026

Exercise price $1.18 per share For the granted options

Vesting 100% On the grant date

Post-transaction position 32,012 stock options Reported after the transaction

Expiration date September 30, 2036 Granted options

Key Terms

2021 Equity Incentive Plan, vest 100%, exercisable

3 terms

2021 Equity Incentive Plan financial

"pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan"

vest 100% financial

"vest 100% on the date of the grant"

exercisable financial

"are exercisable beginning as of that date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many stock options did MAIA director Theagene Jean-Manasse receive?

MAIA director Theagene Jean-Manasse received 32,012 stock options on September 30, 2026. The options were granted under the 2021 Equity Incentive Plan, vested 100% on the grant date, and were exercisable beginning that date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/02/2026 - 04:20 PM Accepted by SEC EDGAR 10/02/2026 - 04:20 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Theagene Jean-Manasse

(Last) (First) (Middle)

444 WEST LAKE STREET, SUITE 1700

(Street)

CHICAGO ILLINOIS 60606

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MAIA Biotechnology, Inc. [ MAIA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$1.18	09/30/2026		A		32,012		09/30/2026(1)	09/30/2036	Common Stock	32,012	$0	32,012	D

Explanation of Responses:

1. The stock options, granted on September 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

	/s/ Jean-Manasse Theagene	10/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)